Unchecked drug price increases hit both patients and hospitals hard. Since 2008, brand name drugs prices have increased 127 percent compared with an 11 percent rise in consumer prices. These increases cut deep into both hospital budgets and services and undermine patient and community health, particularly when patients cannot afford to take their medicines. These increases are simply unsustainable. This week, we joined the Campaign for Sustainable Rx Pricing in support of policy principles designed to help find solutions to high drug prices. These solutions seek to preserve innovation and ensure affordability by increasing transparency, promoting competition and realizing more value. Rising drug prices, their impact and implications are also on the agenda next week at the AHA’s Annual Meeting as the focus of a May 2 Executive Briefing. The time for action is now. As much as anyone, the women and men who work in hospitals recognize the value of innovative, lifesaving medicines but a drug priced beyond our – or a patient’s reach – cannot save anyone’s life. 

Related News Articles

Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
The Centers for Medicare & Medicaid Services Oct. 9 released a request for information and a sample list of prescription drugs it intends to include under…
Headline
The Centers for Medicare & Medicaid Services Oct. 21 will host a webinar on meeting its new hospital price transparency requirements becoming effective Jan…
Headline
The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug…
Headline
The Centers for Medicare & Medicaid Services Sept. 27 announced that average premiums, benefits and plan choices for Medicare Advantage and Part D will…
Headline
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices…